These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 8288662)

  • 1. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
    Colwell CW; Spiro TE; Trowbridge AA; Morris BA; Kwaan HC; Blaha JD; Comerota AJ; Skoutakis VA
    J Bone Joint Surg Am; 1994 Jan; 76(1):3-14. PubMed ID: 8288662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
    Colwell CW; Spiro TE; Trowbridge AA; Stephens JW; Gardiner GA; Ritter MA
    Clin Orthop Relat Res; 1995 Dec; (321):19-27. PubMed ID: 7497668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.
    Eriksson BI; Kälebo P; Anthymyr BA; Wadenvik H; Tengborn L; Risberg B
    J Bone Joint Surg Am; 1991 Apr; 73(4):484-93. PubMed ID: 2013587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group.
    Spiro TE; Johnson GJ; Christie MJ; Lyons RM; MacFarlane DE; Blasier RB; Tremaine MD
    Ann Intern Med; 1994 Jul; 121(2):81-9. PubMed ID: 8017740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.
    Planes A; Vochelle N; Mazas F; Mansat C; Zucman J; Landais A; Pascariello JC; Weill D; Butel J
    Thromb Haemost; 1988 Dec; 60(3):407-10. PubMed ID: 2853459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.
    Faunø P; Suomalainen O; Rehnberg V; Hansen TB; Krøner K; Soimakallio S; Nielsen E
    J Bone Joint Surg Am; 1994 Dec; 76(12):1814-8. PubMed ID: 7989386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.
    Warwick D; Harrison J; Glew D; Mitchelmore A; Peters TJ; Donovan J
    J Bone Joint Surg Am; 1998 Aug; 80(8):1158-66. PubMed ID: 9730125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
    Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
    J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
    J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Leclerc J; Powers PJ; Jay RM; Neemeh J
    Ann Intern Med; 1991 Apr; 114(7):545-51. PubMed ID: 1848054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
    Br J Surg; 1997 Aug; 84(8):1099-103. PubMed ID: 9278651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
    Avikainen V; von Bonsdorff H; Partio E; Kaira P; Hakkinen S; Usenius JP; Kaaja R
    Ann Chir Gynaecol; 1995; 84(1):85-90. PubMed ID: 7645915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial.
    Planes A; Vochelle N; Darmon JY; Fagola M; Bellaud M; Compan D; Saliba E; Weisslinger N; Huet Y
    Drugs; 1996; 52 Suppl 7():47-54. PubMed ID: 9042560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
    Colwell CW; Spiro TE
    Clin Orthop Relat Res; 1995 Oct; (319):215-22. PubMed ID: 7554633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
    Colwell CW; Collis DK; Paulson R; McCutchen JW; Bigler GT; Lutz S; Hardwick ME
    J Bone Joint Surg Am; 1999 Jul; 81(7):932-40. PubMed ID: 10428124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation.
    Menzin J; Richner R; Huse D; Colditz GA; Oster G
    Ann Pharmacother; 1994 Feb; 28(2):271-5. PubMed ID: 8173149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.